A Phase 1/2 interventional study of GNOS-PV02 and INO-9012 in HCC, sponsored by Geneos Therapeutics. Active, not recruiting at 3 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-24.
Sponsored by Geneos Therapeutics · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a single-arm, open-label, multi-site Phase I/IIa study of a personalized neoantigen DNA vaccine (GNOS-PV02) and plasmid encoded IL-12 (INO-9012) in combination with pembrolizumab (MK-3475) in subjects with histologically or cytologically confirmed diagnosis of HCC based on pathology report.
Geneos Therapeutics is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Be willing to use an adequate method of for the course of the study through 150 days after the last dose of study drug (male and female subjects of childbearing potential).
Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.
Exclusion Criteria:
Has untreated active virus (HBV), unless planned antiviral therapy during TKI.
Note: Patients with HBV infection, characterized by positive HBsAg and/or HBcAb with detectable HBV DNA (≥10 IU/ml or above the limit of detection per local lab standard), must be treated with antiviral therapy as per institutional practice to ensure adequate viral suppression (HBV DNA ≤2000 IU/mL) prior to treatment with the study drug. Patients who test positive for HBcAg with undetectable HBV DNA (\<10 IU/ml or under the limit of detection per local lab standard) do not require anti-viral therapy prior to enrollment.
Has received a within 30 days of planned start of study treatment (Cycle 1, Day 1).
Note: The killed virus vaccines used for seasonal influenza vaccines for injection are allowed; however intranasal influenza vaccines (e.g., FluMist®) are live attenuated vaccines and are not allowed. Non-live COVID-19 vaccines are allowed.
Any for treatment with the CELLECTRA® 2000 Device:
Less than two acceptable sites available for ID injection and EP considering the deltoid and anterolateral quadriceps muscles:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
First line therapy with standard of care tyrosine kinase inhibitors (TKI) during which patient-specific GNOS-PV02 will be manufactured. GNOS-PV02 + INO-9012 + Pembrolizumab will be administered upon disease progression or intolerance to TKI.
Biological: GNOS-PV02 · Biological: INO-9012 · Drug: Pembrolizumab · Device: CELLECTRA®2000 EP Device
GNOS-PV02 delivered by intradermal injection and electroporation
INO-9012 delivered by intradermal injection and electroporation
Pembrolizumab administered as an intravenous (IV) infusion
CELLECTRA® 2000 Device is a system indicated for use to enhance the uptake and expression of plasmid-based biologics in order to enhance vaccine efficacy.
Incidence of Treatment-Related Adverse Events
Incidence of treatment-related adverse events (TRAEs), defined as adverse events deemed possibly, probably, or definitely related to study treatment (PTCV, IL-12, electroporation and/or immune checkpoint inhibitor), with onset on or after the first dose and graded according to CTCAE version 5.0.
Time frame: From first study drug administration to approximately 57 months
Neoantigen-Specific T-Cell Response
Neoantigen-specific T-cell immune response measured using interferon-gamma (IFNγ) ELISpot assays in peripheral blood mononuclear cells (PBMCs). Immune responses were assessed as the magnitude and presence of vaccine-induced T-cell responses to patient-specific neoantigens.
Time frame: From baseline (pretreatment) through on-treatment assessments (approximately up to Week 12), with additional exploratory follow-up time points.
Immunogenicity of a Personalized Neoantigen DNA Vaccine as Measured by T-cell Activation and Cytolytic Cell Phenotype in PBMCs Using Flow Cytometry
Immunogenicity assessed by flow cytometry in peripheral blood mononuclear cells (PBMCs), including T-cell activation (CD69+CD107a+), proliferation (Ki67+) and cytolytic phenotype (GZMA+PRF1+) in CD4+ and CD8+ T-cell populations following stimulation with personalized neoantigen vaccine (PTCV) compared to unstimulated control. Results are summarized as mean percentage of marker-positive T-cell populations among CD4+ or CD8+ T cells. Measurements were performed under unstimulated and antigen-stimulated conditions and data were averaged across the timepoints for the 4 subjects.
Time frame: Assessments completed at Weeks 9 or Weeks 12 post-treatment for 4 subjects.
Objective Response Rate (ORR)
Objective response rate, defined as the proportion of patients achieving a complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, as assessed by investigator review.
Time frame: From first dose to first documented disease progression or death, up to 60 months
Anti-tumor Activity as Measured by Objective Response Rate (ORR) by iRECIST
Objective response rate (ORR) defined as the proportion of patients achieving an immune complete response (iCR) or immune partial response (iPR) according to immune Response Evaluation Criteria in Solid Tumors (iRECIST), as assessed by investigator review.
Time frame: From treatment initiation to first documented disease progression or death. Up to 60 months.
Anti-tumor Activity as Measured by Duration of Response (DOR)
Duration of response defined as the time from first documented confirmed response (complete or partial response) to disease progression or death from any cause, whichever occurred first, assessed according to RECIST version 1.1 using Kaplan-Meier estimation.
Time frame: From first documented response until disease progression or death, assessed up to approximately 5 years.
Disease Control Rate (DCR)
Disease control rate defined as the proportion of participants achieving a complete response (CR), partial response (PR), or stable disease (SD) according to RECIST version 1.1, as assessed by investigator review.
Time frame: From baseline through disease progression; dosing can occur for up to 5 years. Tumor assessments performed every 9 weeks through Week 54 and every 12 weeks thereafter until progression or study end (up to 5 years).
Progression-Free Survival (PFS)
Progression-free survival defined as the time from first dose of study treatment to the first documented radiographic disease progression according to RECIST version 1.1 or death from any cause, whichever occurred first.
Time frame: From first dose of study treatment until disease progression or death, assessed up to approximately 5 years.
Anti-tumor Activity as Measured by Progression Free Survival (PFS) as Assessed by iRECIST
Progression-free survival (PFS) defined as the time from first dose of study treatment to confirmed progressive disease or death from any cause, whichever occurred first, assessed according to immune Response Evaluation Criteria in Solid Tumors (iRECIST) using Kaplan-Meier estimation.
Time frame: From first dose of study treatment until confirmed disease progression or death, assessed up to approximately 5 years.
Overall Survival (OS)
Overall survival defined as the time from first dose of study treatment to death from any cause.
Time frame: From first dose of study treatment until death from any cause, with follow up conducted for up to approximately 5 years.
Male and female subjects with advanced HCC currently receiving or scheduled to receive first-line treatment with sorafenib or lenvatinib, will be enrolled in this study. Combination therapy with GNOS-PV02 and pembrolizumab will begin after discontinuation of first-line lenvatinib or sorafenib. Enrollment period: 3 years.
| Milestone | GNOS-PV02 + INO-9012 Followed by Electroporation in Combination With Pembrolizumab |
|---|---|
| Started | 36 |
| Completed | 34 |
| Not completed | 2 |
| Withdrew: Adverse event | 2 |
Incidence of treatment-related adverse events (TRAEs), defined as adverse events deemed possibly, probably, or definitely related to study treatment (PTCV, IL-12, electroporation and/or immune checkpoint inhibitor), with onset on or after the first dose and graded according to CTCAE version 5.0.
| participants | GNOSPV02 + pIL12 + Pembrolizumab |
|---|---|
| Participants with Grade 1 Treatment-Related Adverse Events | 25 |
| Participants with Grade 2 Treatment-Related Adverse Events | 13 |
| Participants with Grade 3 Treatment-Related Adverse Events | 2 |
| Participants with Grade 4 Treatment-Related Adverse Events | 0 |
| Participants with Grade 5 Treatment-Related Adverse Events | 0 |
Neoantigen-specific T-cell immune response measured using interferon-gamma (IFNγ) ELISpot assays in peripheral blood mononuclear cells (PBMCs). Immune responses were assessed as the magnitude and presence of vaccine-induced T-cell responses to patient-specific neoantigens.
| Participants | GNOSPV02 + pIL12 + Pembrolizumab |
|---|---|
| Neoantigen-Specific T-Cell Response | 19 |
Immunogenicity assessed by flow cytometry in peripheral blood mononuclear cells (PBMCs), including T-cell activation (CD69+CD107a+), proliferation (Ki67+) and cytolytic phenotype (GZMA+PRF1+) in CD4+ and CD8+ T-cell populations following stimulation with personalized neoantigen vaccine (PTCV) compared to unstimulated control. Results are summarized as mean percentage of marker-positive T-cell populations among CD4+ or CD8+ T cells. Measurements were performed under unstimulated and antigen-stimulated conditions and data were averaged across the timepoints for the 4 subjects.
| Percent (%) | GNOS-PV02 + INO-9012 Followed by Electroporation in Combination With Pembrolizumab |
|---|---|
| CD4+ T-cell activation (CD69+CD107a+) - Unstimulated | 0.53 (0.26 to 0.75) |
| CD4+ T-cell activation (CD69+CD107a+) - Stimulated | 2.075 (0.35 to 5.215) |
| CD8+ T-cell activation (CD69+CD107a+) - Unstimulated | 0.258 (0.11 to 0.45) |
| CD8+ T-cell activation (CD69+CD107a+) - Stimulated | 0.6165 (0.213 to 0.95) |
| CD4+ T-cell proliferation (Ki67+) - Unstimulated | 1.3775 (0.65 to 2.33) |
| CD4+ T-cell proliferation (Ki67+) - Stimulated | 3.20025 (2.103 to 4.88) |
| CD8+ T-cell proliferation (Ki67+) - Unstimulated | 1.335 (0.89 to 1.81) |
| CD8+ T-cell proliferation (Ki67+) - Stimulated | 4.21275 (1.445 to 7.608) |
| CD8+ cytolytic phenotype (Ki67+GZMA+PRF1+) - Unstimulated | 0.13575 (0 to 0.34) |
| CD8+ cytolytic phenotype (Ki67+GZMA+PRF1+) - Stimulated | 0.41025 (0.025 to 0.948) |
| CD8+ activation/cytolytic phenotype (CD69+CD107a+GZMA+PRF1+) - Unstimulated | 0.17725 (0.079 to 0.29) |
| CD8+ activation/cytolytic phenotype (CD69+CD107a+GZMA+PRF1+) - Stimulated | 0.38075 (0.105 to 0.658) |
Objective response rate, defined as the proportion of patients achieving a complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, as assessed by investigator review.
| Participants | GNOSPV02 + pIL12 + Pembrolizumab |
|---|---|
| Complete Response | 3 |
| Partial Response | 6 |
| Stable Disease | 11 |
| Progressive Disease | 14 |
| Not Evaluable | 2 |
Objective response rate (ORR) defined as the proportion of patients achieving an immune complete response (iCR) or immune partial response (iPR) according to immune Response Evaluation Criteria in Solid Tumors (iRECIST), as assessed by investigator review.
| Percent | GNOS PV02 + pIL 12 + Pembrolizumab |
|---|---|
| Anti-tumor Activity as Measured by Objective Response Rate (ORR) by iRECIST | 0.0 (0.0 to 9.7) |
Duration of response defined as the time from first documented confirmed response (complete or partial response) to disease progression or death from any cause, whichever occurred first, assessed according to RECIST version 1.1 using Kaplan-Meier estimation.
| Months | GNOS PV02 + pIL 12 + Pembrolizumab |
|---|---|
| Anti-tumor Activity as Measured by Duration of Response (DOR) | NA (13.4 to —) |
Disease control rate defined as the proportion of participants achieving a complete response (CR), partial response (PR), or stable disease (SD) according to RECIST version 1.1, as assessed by investigator review.
| Percent | GNOS PV02 + pIL 12 + Pembrolizumab |
|---|---|
| Disease Control Rate (DCR) | 55.6 (38.1 to 72.1) |
Progression-free survival defined as the time from first dose of study treatment to the first documented radiographic disease progression according to RECIST version 1.1 or death from any cause, whichever occurred first.
| Months | GNOSPV02 + pIL12 + Pembrolizumab |
|---|---|
| Progression-Free Survival (PFS) | 4.5 (2.3 to 14.9) |
Progression-free survival (PFS) defined as the time from first dose of study treatment to confirmed progressive disease or death from any cause, whichever occurred first, assessed according to immune Response Evaluation Criteria in Solid Tumors (iRECIST) using Kaplan-Meier estimation.
| Months | GNOS PV02 + pIL 12 + Pembrolizumab |
|---|---|
| Anti-tumor Activity as Measured by Progression Free Survival (PFS) as Assessed by iRECIST | 20.1 (5.4 to NA) |
Overall survival defined as the time from first dose of study treatment to death from any cause.
| Months | GNOS PV02 + pIL 12 + Pembrolizumab |
|---|---|
| Overall Survival (OS) | 18.3 (9.0 to 30.2) |
Collected over From first study drug administration to approximately 57 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| GNOS-PV02 + INO-9012 Followed by Electroporation in Combination With Pembrolizumab | 24/36 (66.7%) | 19/36 (52.8%) | 27/36 (75%) |
| Event | GNOS-PV02 + INO-9012 Followed by Electroporation in Combination With Pembrolizumab |
|---|---|
| Abdominal painGastrointestinal disorders | 2/36 |
| Lower respiratory tract infectionInfections and infestations | 2/36 |
| PneumoniaInfections and infestations | 2/36 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 2/36 |
| AnaemiaBlood and lymphatic system disorders | 2/36 |
| Abdominal pain upperGastrointestinal disorders | 1/36 |
| Anal fissureGastrointestinal disorders | 1/36 |
| AscitesGastrointestinal disorders | 1/36 |
| ColitisGastrointestinal disorders | 1/36 |
| Faeces discolouredGastrointestinal disorders | 1/36 |
| Event | GNOS-PV02 + INO-9012 Followed by Electroporation in Combination With Pembrolizumab |
|---|---|
| FatigueGeneral disorders | 14/36 |
| DiarrhoeaGastrointestinal disorders | 14/36 |
| Decreased appetiteMetabolism and nutrition disorders | 10/36 |
| Abdominal painGastrointestinal disorders | 9/36 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 9/36 |
| Back painMusculoskeletal and connective tissue disorders | 8/36 |
| HeadacheNervous system disorders | 8/36 |
| COVID-19Infections and infestations | 8/36 |
| Upper respiratory tract infectionInfections and infestations | 8/36 |
| NauseaGastrointestinal disorders | 7/36 |
The baseline analysis population consisted of 36 patients with advanced hepatocellular carcinoma who initiated study treatment and formed the modified intention-to-treat population.
| Age, Categorical(Participants) | Single Arm, Interventional |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 16 |
| >=65 years | 20 |
| Age, Continuous(Years) | Single Arm, Interventional |
|---|---|
| Median | 68 (40 to 83) |
| Sex: Female, Male(Participants) | Single Arm, Interventional |
|---|---|
| Female | 11 |
| Male | 25 |
| Ethnicity (NIH/OMB)(Participants) | Single Arm, Interventional |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 36 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(Participants) | Single Arm, Interventional |
|---|---|
| United States | 8 |
| New Zealand | 28 |
| Race (NIH/OMB)(Participants) | Single Arm, Interventional |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 6 |
| Native Hawaiian or Pacific Islander | 2 |
| Black or African American | 1 |
| White | 21 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Other | 6 |
| ECOG Performance Status(Participants) | Single Arm, Interventional |
|---|---|
| ECOG 0 | 8 |
| ECOG 1 | 14 |
| ECOG 2 | 10 |
| ECOG 3 | 3 |
| ECOG 4 | 0 |
| ECOG 5 | 0 |
| UNKNOWN | 1 |
| Child-Pugh Classification(Participants) | Single Arm, Interventional |
|---|---|
| Class A | 36 |
| Class B or C | 0 |
7 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2020 to primary completion in Nov 2024, 56 months.
Results were first posted in Sep 2026, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rocakinogene sifuplasmid
Geneos Therapeutics